PCSK9 Protein (AA 31-692) (His tag)

N° du produit ABIN7275415

Détail du produit

Antigène: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Type de proteíne: Recombinant

Attributs du protein: AA 31-692

Origine: Humain

Source: HEK-293 Cells

Purification/Conjugué: Cette PCSK9 protéine est marqué à la His tag.

Fonction: Human PCSK9 Protein

Séquence: Gln31-Gln692

Attributs du produit: Recombinant Human PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln31-Gln692.

Pureté: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1EU per μg by the LAL method.

Biological Activity Comment: Immobilized Human PCSK9, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-PCSK9 antibody, hFc Tag with the EC50 of 0.16μg/ml determined by ELISA. The affinity constant of 0.35 nM as determined in SPR assay (Biacore T200). See testing image for detail.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Supplied as 0.22μm filtered solution in 20 mM PB, 300 mM NaCl, 10 % Glycerol ( pH 7.4).

Stock: -80 °C

Stockage commentaire: Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Date de péremption: 12 months

Détail du antigène

Antigène: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Autre désignation: PCSK9 (PCSK9 Produits)

Synonymes: FH3 Protein, HCHOLA3 Protein, LDLCQ1 Protein, NARC-1 Protein, NARC1 Protein, PC9 Protein, AI415265 Protein, AI747682 Protein, Narc1 Protein, proprotein convertase subtilisin/kexin type 9 Protein, proprotein convertase subtilisin/kexin type 9 L homeolog Protein, PCSK9 Protein, pcsk9.L Protein, pcsk9 Protein, Pcsk9 Protein

Sujet: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

Poids moléculaire: Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Tris-Bis PAGE result.